Learn about projects in Uganda and East Africa contributed to by staff at LSHTM and MRC/UVRI.
ACACIA study
This study aims to determine whether adding liposomal amphotericin to standard fluconazole therapy improves 24-week cryptococcal meningitis–free survival among individuals with asymptomatic cryptococcal antigenemia.
BREATHER Plus
A randomized open label 3-arm, 96-week trial evaluating the efficacy, safety and acceptability of weekends off dolutegravir-based antiretroviral therapy (ART) and monthly long-acting injecable ART compared to daily dolutegravir-based ART in virologically suppressed HIV-infected children and adolescents in sub-Saharan Africa
KAF156
The proposed trial is sponsored by Norvatis. It is a multicentre, open-label, randomized, parallel-group study in adults and children with confirmed and uncomplicated P. falciparum malaria. The purpose of this study is to determine the effective and tolerable dose of KAF156, a new antimalarial molecule that can be administered in combination with a Solid Dispersion Formulation of lumefantrine (LUM-SDF) for the shortest treatment duration possible.
EBOVAC
A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults
NCI-LEIDOS
This study investigates Kaposi sarcoma-associated herpesvirus (KSHV) infection using data from the Entebbe Mother and Baby Study (EMABS) and the General Population Cohort (GPC). Building on previous research, it explores the relationship between parasite infections and KSHV, as well as factors linked to high lytic KSHV antibody titres. A case-control study of Kaposi sarcoma will be conducted to validate hypotheses generated from earlier findings, advancing understanding of KSHV pathogenesis in African populations.
Obuntu Bulamu Randomized Control Trial
The Obuntu Bulamu randomized control trial is a four-year research study conducted across 20 primary schools in Wakiso and Masaka districts of Uganda. It seeks to investigate the impact of Obuntu Bulamu project interventions between 2017-2019 on participation, inclusion, and quality of life of 200 children with disabilities.
Kilgoris Study
Kilgoris (Masai for ‘Unstable’ to describe the ever-changing nature of HIV-1) is a clinical study that investigates the ability of the human body to control the amount of free Human Immunodeficiency Virus-1 (HIV-1) early in infection without antiretroviral drugs.
IMPALA: Improving HIV Outcomes in Africa With Long Acting Antiretrovirals
IMPALA seeks to tackle the underlying challenge of maintaining virological suppression in people living with HIV in sub-Saharan Africa by investigating novel long-acting antiretrovirals.
MENISCUS Trial
Contacts: Sarah Harman
Partners: MRC/UVRI & LSHTM Uganda Research Unit, WoMena Uganda, Makerere University Uganda and University College London.
Major donors: Foreign, Commonwealth & Development Office, Medical Research Council (MRC), UKRI,National Institute for Health Research (NIHR), Wellcome
Evaluating the impact of a multi-component menstrual health intervention in Ugandan secondary schools on girls’ education, health, and wellbeing.The aim of the MENISCUS trial is to assess whether the intervention improves educational attainment, mental health symptoms, menstrual management and quality of life outcomes among girls in secondary school in Uganda.
THRiVE
Contacts: Professor Nelson Sewankambo, Professor David Mabey
Partners:
- Uganda: Makerere University (lead), Gulu University, Uganda Virus Research Institute (UVRI)
- Tanzania: Kilimanjaro Christian Medical University College (KCMUC), National Institute for Medical Research (NIMR)
- Kenya: International Centre of Insect Physiology and Ecology
- UK: London School of Hygiene & Tropical Medicine (LSHTM); University of Cambridge
Donors: THRiVE-2 is part of the Developing Excellence in Leadership and Training in Africa (DELTAS Africa) programme which is a scheme funded by the Wellcome Trust in partnership with the UK Department for International Development.
THRiVE’s mission is to empower African Institutions to become research engines for health innovations and evidence-based healthcare practices and policies.
Training Health Researchers into Vocational Excellence in East Africa (THRiVE-2) partnership is a training programme that aims to transform East African universities into world class research hubs for key emerging health issues in the region. By training and developing the scientific careers of PhD students and post-doctoral fellows, THRiVE-2 will build on the successes of THRiVE, a regional network of research excellence, to create research leaders in infectious diseases, neglected tropical disease, maternal, neonatal and reproductive health, and non-communicable diseases.